Goldman Sachs initiated coverage of Annexon (ANNX) with a Neutral rating and $7 price target Annexon is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory diseases via inhibition of the complement pathway, the analyst tells investors in a research note. Goldman views the company’s Phase data for vonaprument in geographic atrophy in Q4 as a “binary event.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon: Advancing Complement Pipeline and Strong Cash Runway Support Buy Rating; $11 Price Target Reiterated
- Annexon reports Q1 EPS (23c), consensus (30c)
- Cyber Risks Threaten Annexon Biosciences’ Clinical Operations, Reputation and Financial Health
- Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
- Annexon files automatic mixed securities shelf